53.60 0.00 (0.00%)
After hours: 4:51PM EST
| Previous Close | 50.90 |
| Open | 50.70 |
| Bid | 51.35 x 800 |
| Ask | 53.76 x 800 |
| Day's Range | 50.63 - 55.13 |
| 52 Week Range | 22.50 - 57.87 |
| Volume | 711,320 |
| Avg. Volume | 270,532 |
| Market Cap | 1.248B |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.26 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 49.14 |
Inspire Medical Systems, Inc. (INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), announced today that Horizon Blue Cross Blue Shield of New Jersey (“Horizon BCBSNJ”) has issued a positive coverage policy of Inspire therapy. This is the second coverage policy issued by a Blue Cross Blue Shield Association (“BCBSA”) healthcare plan following BCBSA Evidence Street’s January 7, 2019 report, which stated that there is sufficient evidence to determine that Inspire therapy results in a meaningful improvement in net health outcomes for patients meeting specified criteria.
Inspire Medical Systems, Inc. (INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), announced today that Blue Cross of Idaho has issued a positive coverage policy of Inspire therapy. This is the first coverage policy issued following BCBS Evidence Street’s January 7, 2019 report, which stated there is sufficient evidence to determine that Inspire therapy results in a meaningful improvement in net health outcomes for patients meeting specified criteria. Blue Cross of Idaho, the state of Idaho’s leading health insurer, is a not-for-profit mutual insurance company covering approximately 500,000 members. Blue Cross of Idaho is an independent licensee of the Blue Cross and Blue Shield Association (BCBSA).
Inspire Medical Systems, Inc. (INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), announced today that the Blue Cross Blue Shield Association's (“BCBSA”) Evidence Street issued a positive assessment of Inspire therapy to its members. BCBSA is a national federation of 36 Blue Cross and Blue Shield (“BCBS”) companies that, when combined, is one of the leading health associations in the U.S.
MINNEAPOLIS, Dec. 19, 2018 -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative.
Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that the underwriters of its previously announced offering of 2,500,000 shares of its common stock, consisting of 1,500,000 shares offered by Inspire and 1,000,000 shares offered by certain stockholders of Inspire (the “Selling Stockholders”), have exercised in full their option to purchase an additional 375,000 shares of its common stock at a public offering price of $40.00 per share, less underwriting discounts and commissions. The exercise of the option brings the total shares of common stock sold by Inspire in the offering to 1,875,000 shares.
While small-cap stocks, such as Inspire Medical Systems, Inc. (NYSE:INSP) with its market cap of US$947m, are popular for their explosive growth, investors should also be aware of their balance Read More...
Inspire Medical Systems, Inc. (INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today the pricing of the previously announced offering of 2,500,000 shares of its common stock, consisting of 1,500,000 shares offered by Inspire and 1,000,000 shares offered by certain stockholders of Inspire (the “Selling Stockholders”), at a public offering price of $40.00 per share, before underwriting discounts and commissions. In addition, Inspire has granted the underwriters a 30-day option to purchase up to an additional 375,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.
Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today the commencement of a proposed public offering of 2,500,000 shares of its common stock, consisting of 1,500,000 shares offered by Inspire and 1,000,000 shares offered by certain stockholders of Inspire (the “Selling Stockholders”). Inspire also expects to grant the underwriters a 30-day option to purchase up to an additional 375,000 shares of common stock. Inspire will not receive any proceeds from the sale of common stock offered by the Selling Stockholders.
Inspire Medical Systems, Inc. (INSP) ("Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (OSA), announced today the publication of data from the first 508 Inspire therapy patients included in the 2,500-patient ADHERE registry. The data demonstrated that Inspire therapy is an effective treatment option with high patient satisfaction and low adverse events. These results represent the largest international data set for Inspire therapy generated to date. The publication, entitled “Post-Approval Upper Airway Stimulation Predictors of Treatment Efficacy in the Adhere Registry,” is available online (http://erj.ersjournals.com/content/early/2018/10/25/13993003.01405-2018) in the European Respiratory Journal, the flagship journal of the European Respiratory Society. The lead authors of the publication are Dr. Clemens Heiser of the Technische Universität in Munich, and Dr. Maurits Boon of Thomas Jefferson University Hospital.
MINNEAPOLIS, Nov. 14, 2018 -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative.
MINNEAPOLIS, Nov. 06, 2018 -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative.
Inspire Medical Systems, Inc. (INSP) ("Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (OSA), announced today that its management team will be presenting at the Stifel 2018 Healthcare Conference on November 13, 2018 at the Lotte New York Palace Hotel in New York. Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 9) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Arrowhead Pharmaceuticals ...
WallStEquities.com monitors four Medical Appliances and Equipment stocks, namely: Globus Medical Inc. (NYSE: GMED), Inspire Medical Systems Inc. (NYSE: INSP), InspireMD Inc. (NYSE AMER: NSPR), and LivaNova PLC (NASDAQ: LIVN). Audubon, Pennsylvania headquartered Globus Medical Inc.'s shares recorded a trading volume of 636,640 shares last Friday.